New opportunities in the treatment of patients with multiple sclerosis (Resolution of the Council of Experts on April 23, 2022, Moscow, JSC «BIOCAD»)
One of the target areas for the development of the Russian pharmaceutical industry at present is the development of next-in-class drugs medicines. These are original, patent-protected drugs that act on known biological targets, improved or modified in structure and mechanism of action compared to existing, successfully proven medicine. The article presents the results of an expert council on the management of patients with multiple sclerosis and the place of new original medicines of the JSC BIOCAD company (SamPEG-IFN-β1a and divozilimab) in multiple sclerosis therapy algorithm.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:122 |
|---|---|
| Enthalten in: |
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova - 122(2022), 7. Vyp. 2 vom: 02., Seite 84-88 |
| Sprache: |
Russisch |
|---|
| Weiterer Titel: |
Novye vozmozhnosti v terapii patsientov s rasseyannym sklerozom» (Rezolyutsiya soveta ekspertov 23 aprelya 2022 goda, Moskva, AO «BIOKAD») |
|---|
| Beteiligte Personen: |
Spirin, N N [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Divozilimab |
|---|
| Anmerkungen: |
Date Completed 02.08.2022 Date Revised 11.08.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.17116/jnevro202212207284 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344322440 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344322440 | ||
| 003 | DE-627 | ||
| 005 | 20231226022510.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.17116/jnevro202212207284 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1147.xml |
| 035 | |a (DE-627)NLM344322440 | ||
| 035 | |a (NLM)35912562 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Spirin, N N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a New opportunities in the treatment of patients with multiple sclerosis (Resolution of the Council of Experts on April 23, 2022, Moscow, JSC «BIOCAD») |
| 246 | 3 | 3 | |a Novye vozmozhnosti v terapii patsientov s rasseyannym sklerozom» (Rezolyutsiya soveta ekspertov 23 aprelya 2022 goda, Moskva, AO «BIOKAD») |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.08.2022 | ||
| 500 | |a Date Revised 11.08.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a One of the target areas for the development of the Russian pharmaceutical industry at present is the development of next-in-class drugs medicines. These are original, patent-protected drugs that act on known biological targets, improved or modified in structure and mechanism of action compared to existing, successfully proven medicine. The article presents the results of an expert council on the management of patients with multiple sclerosis and the place of new original medicines of the JSC BIOCAD company (SamPEG-IFN-β1a and divozilimab) in multiple sclerosis therapy algorithm | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SamPEG-IFN-β1a | |
| 650 | 4 | |a divozilimab | |
| 650 | 4 | |a multiple sclerosis | |
| 650 | 4 | |a next-in-class medicine | |
| 700 | 1 | |a Vlasov, Ya V |e verfasserin |4 aut | |
| 700 | 1 | |a Zakharova, M N |e verfasserin |4 aut | |
| 700 | 1 | |a Khachanova, N V |e verfasserin |4 aut | |
| 700 | 1 | |a Popova, E V |e verfasserin |4 aut | |
| 700 | 1 | |a Khabirov, F A |e verfasserin |4 aut | |
| 700 | 1 | |a Totolyan, N A |e verfasserin |4 aut | |
| 700 | 1 | |a Sivertseva, S A |e verfasserin |4 aut | |
| 700 | 1 | |a Goncharova, Z A |e verfasserin |4 aut | |
| 700 | 1 | |a Korsunskaya, L L |e verfasserin |4 aut | |
| 700 | 1 | |a Yakushina, T I |e verfasserin |4 aut | |
| 700 | 1 | |a Matvievskaya, O V |e verfasserin |4 aut | |
| 700 | 1 | |a Simaniv, T O |e verfasserin |4 aut | |
| 700 | 1 | |a Boyko, A N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova |d 1997 |g 122(2022), 7. Vyp. 2 vom: 02., Seite 84-88 |w (DE-627)NLM074605267 |x 1997-7298 |7 nnns |
| 773 | 1 | 8 | |g volume:122 |g year:2022 |g number:7. Vyp. 2 |g day:02 |g pages:84-88 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.17116/jnevro202212207284 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 122 |j 2022 |e 7. Vyp. 2 |b 02 |h 84-88 | ||